Cargando…

Dose-Response Effects of Insulin Glargine in Type 2 Diabetes

OBJECTIVE: To determine the pharmacokinetic and pharmacodynamic dose-response effects of insulin glargine administered subcutaneously in individuals with type 2 diabetes. RESEARCH DESIGN AND METHODS: Twenty obese type 2 diabetic individuals (10 male and 10 female, aged 50 ± 3 years, with BMI 36 ± 2...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Zhihui, Hedrington, Maka S., Gogitidze Joy, Nino, Briscoe, Vanessa J., Richardson, M. Antoinette, Younk, Lisa, Nicholson, Wendell, Tate, Donna B., Davis, Stephen N.
Formato:	Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2010
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2890358/ https://www.ncbi.nlm.nih.gov/pubmed/20357371 http://dx.doi.org/10.2337/dc09-2011

Ejemplares similares

Effects of Acute Hypoglycemia on Inflammatory and Pro-atherothrombotic Biomarkers in Individuals With Type 1 Diabetes and Healthy Individuals
por: Gogitidze Joy, Nino, et al.
Publicado: (2010)

Effects of Antecedent GABA A Receptor Activation on Counterregulatory Responses to Exercise in Healthy Man
por: Hedrington, Maka S., et al.
Publicado: (2015)

Effects of γ-Aminobutyric Acid A Receptor Activation on Counterregulatory Responses to Subsequent Exercise in Individuals With Type 1 Diabetes
por: Hedrington, Maka S., et al.
Publicado: (2016)

Pharmacokinetics and pharmacodynamics of insulin glargine–insulin glulisine basal-bolus and twice-daily premixed analog insulin in type 1 diabetes mellitus patients during three standardized meals
por: Lamos, Elizabeth Mary, et al.
Publicado: (2015)

Effects of Acute and Antecedent Hypoglycemia on Endothelial Function and Markers of Atherothrombotic Balance in Healthy Humans
por: Joy, Nino G., et al.
Publicado: (2015)

Effects of Antecedent GABA(A) Activation With Alprazolam on Counterregulatory Responses to Hypoglycemia in Healthy Humans
por: Hedrington, Maka S., et al.
Publicado: (2010)

The role of empagliflozin in the management of type 2 diabetes by patient profile
por: Hedrington, Maka S, et al.
Publicado: (2015)

Sexual Dimorphism in Glucose and Lipid Metabolism during Fasting, Hypoglycemia, and Exercise
por: Hedrington, Maka S., et al.
Publicado: (2015)

Concentrated insulins: the new basal insulins
por: Lamos, Elizabeth M, et al.
Publicado: (2016)

Glargine and degludec: Solution behaviour of higher dose synthetic insulins
por: Adams, Gary G., et al.
Publicado: (2017)

Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus
por: Linnebjerg, Helle, et al.
Publicado: (2016)

Insulin glargine overdose
por: Doğan, Fatma Sarı, et al.
Publicado: (2012)

Effects of Differing Antecedent Increases of Plasma Cortisol on Counterregulatory Responses During Subsequent Exercise in Type 1 Diabetes
por: Bao, Shichun, et al.
Publicado: (2009)

Immunogenicity and Efficacy of Insulin Glargine Biosimilar Ezelin versus Originator Insulin Glargine in Patients with Type 2 Diabetes
por: Tarigan, Tri Juli Edi, et al.
Publicado: (2021)

Insulin analogues dosing and costs - comparing real-life daily doses of insulin detemir and insulin glargine in type 2 diabetes patients
por: Jakobsen, Marie, et al.
Publicado: (2012)

Insulin glargine and the risk of cancer
por: Ahmed, FA
Publicado: (2010)

Effects of the Selective Serotonin Reuptake Inhibitor Fluoxetine on Counterregulatory Responses to Hypoglycemia in Individuals With Type 1 Diabetes
por: Briscoe, Vanessa J., et al.
Publicado: (2008)

Efficacy and safety of LY2963016 insulin glargine in patients with type 1 and type 2 diabetes previously treated with insulin glargine
por: Hadjiyianni, I., et al.
Publicado: (2016)

Immunogenicity of LY2963016 insulin glargine and Lantus® insulin glargine in Chinese patients with type 1 or type 2 diabetes mellitus
por: Wang, Weimin, et al.
Publicado: (2022)

Potential Formula for the Calculation of Starting and Incremental Insulin Glargine Doses: ALOHA Subanalysis
por: Kadowaki, Takashi, et al.
Publicado: (2012)

Clinical Characteristics and Glycemic Outcomes of Patients with Type 2 Diabetes Requiring Maximum Dose Insulin Glargine/Lixisenatide Fixed-Ratio Combination or Insulin Glargine in the LixiLan-L Trial
por: Blonde, Lawrence, et al.
Publicado: (2019)

Insulin Glargine and Acarbose in the treatment of elderly patients with diabetes
por: Li, Jing, et al.
Publicado: (2019)

Effects of Intensive Therapy and Antecedent Hypoglycemia on Counterregulatory Responses to Hypoglycemia in Type 2 Diabetes
por: Davis, Stephen N., et al.
Publicado: (2009)

Comparison of Combined Tofogliflozin and Glargine, Tofogliflozin Added to Insulin, and Insulin Dose-Increase Therapy in Uncontrolled Type 2 Diabetes
por: Suzuki, Katsunori, et al.
Publicado: (2016)

Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with type 1 or type 2 diabetes mellitus
por: Ilag, L. L., et al.
Publicado: (2016)

Single‐dose euglycaemic clamp studies demonstrating pharmacokinetic and pharmacodynamic similarity between MK‐1293 insulin glargine and originator insulin glargine (Lantus) in subjects with type 1 diabetes and healthy subjects
por: Crutchlow, Michael F., et al.
Publicado: (2017)

Comparison of Insulin Detemir and Insulin Glargine for Hospitalized Patients on a Basal-Bolus Protocol
por: Davis, Sondra, et al.
Publicado: (2017)

Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml
por: Steinstraesser, A, et al.
Publicado: (2014)

Correction: Potential Formula for the Calculation of Starting and Incremental Insulin Glargine Doses: ALOHA Subanalysis
Publicado: (2014)

Correction: Potential Formula for the Calculation of Starting and Incremental Insulin Glargine Doses: ALOHA Subanalysis
Publicado: (2014)

How much is too much? Outcomes in patients using high‐dose insulin glargine
por: Reid, T., et al.
Publicado: (2015)

Plasma Exposure to Insulin Glargine and Its Metabolites M1 and M2 After Subcutaneous Injection of Therapeutic and Supratherapeutic Doses of Glargine in Subjects With Type 1 Diabetes
por: Bolli, Geremia B., et al.
Publicado: (2012)

Insulin Glargine in the Treatment of Type 1 and Type 2 Diabetes
por: Barnett, Anthony H
Publicado: (2006)

The Evolution of Insulin Glargine and its Continuing Contribution to Diabetes Care
por: Hilgenfeld, Rolf, et al.
Publicado: (2014)

Insulin glargine in pediatric patients with type 1 diabetes in Japan
por: Urakami, Tatsuhiko, et al.
Publicado: (2014)

Glargine versus regular insulin protocol in feline diabetic ketoacidosis
por: Zeugswetter, Florian K., et al.
Publicado: (2021)

A case of hypersensitivity to soluble and isophane insulins but not to insulin glargine
por: Belhekar, Mahesh N., et al.
Publicado: (2015)

Hypersensitivity reaction associated with subcutaneous glargine insulin therapy in a cat
por: Murphy, Lisa A, et al.
Publicado: (2016)

Effects of a Selective Serotonin Reuptake Inhibitor, Fluoxetine, on Counterregulatory Responses to Hypoglycemia in Healthy Individuals
por: Briscoe, Vanessa J., et al.
Publicado: (2008)

Insulin Glargine and Cancer Risk in Patients with Diabetes: A Meta-Analysis
por: Tang, Xulei, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_n1l9pl6mjj7kl2nhqlt0ohsb1c